Outcome of Board Meeting held on February 11, 2026 is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mercury Laboratories' board approved unaudited Q3 FY26 results on February 11, 2026. Revenue from operations for Q3 FY26 stood at around Rs 1,835 lakhs, down roughly 6% from Rs 1,957 lakhs in Q3 FY25, with total income at Rs 1,866 lakhs versus Rs 2,010 lakhs. For the nine-month period, revenue grew modestly to Rs 5,549 lakhs from Rs 5,444 lakhs. Profit after tax jumped sharply to Rs 360.8 lakhs for 9M FY26 from Rs 203.5 lakhs in 9M FY25, a rise of about 77%, driven by lower other expenses and improved operating margins. Q3 PAT was Rs 99.75 lakhs versus Rs 119.28 lakhs, down about 16% year-on-year. EPS for 9M came in at Rs 30.07 versus Rs 16.96. The company booked a Rs 39.49 lakh exceptional loss on account of new Labour Codes impacting gratuity calculations. Statutory auditors Naresh & Co. issued an unqualified limited review report.
Strong 9-month profit growth and margin expansion are positive signals for shareholders, though the quarterly revenue dip and exceptional charge warrant attention. Overall, the results suggest improving profitability despite weaker top-line in Q3, which may support a stable to positive stock reaction.